Showing results (161-170 of 231) with videos related to

Sort By:
Pageof 24
Ejhaem|August 21, 2023
The prognostic impact of t(11;14) in multiple myeloma: A real-world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)Kenneth Jc Lim, Cameron Wellard, Dipti Talaulikar, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 13, 2026
Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk GroupsGhassan Zammar, Bradley Augustson, Elizabeth Moore, et al.
JAMA Neurology|April 5, 2016
Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell TransplantationAdam Bryant, Harold Atkins, C Elizabeth Pringle, et al.
Blood Cancer Journal|January 25, 2022
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trialMeletios A Dimopoulos, Fredrik Schjesvold, Vadim Doronin, et al.
JAACAP Open|September 9, 2025
Suicidal Thoughts and Behaviors in Elementary School-Aged Youth: A Pilot Study in 5- to 10-Year-OldsAdam Bryant Miller, Margaret A Sheridan, Andrea Pelletier-Baldelli, et al.
Blood Advances|December 31, 2021
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 studyGareth P Gregory, Shaji Kumar, Ding Wang, et al.
American Journal of Hematology|July 28, 2025
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular EventsEvangelos Terpos, Suzanne Trudel, María-Victoria Mateos, et al.
Psychoneuroendocrinology|October 9, 2023
Threat exposure moderates associations between neural and physiological indices of emotion reactivity in adolescent femalesMeredith Gruhn, Adam Bryant Miller, Tory A Eisenlohr-Moul, et al.
Scientific Reports|March 9, 2018
Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myelomaNicholas A Gherardin, Liyen Loh, Lorenztino Admojo, et al.
Blood Cancer Journal|December 27, 2025
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCOGurdeep Parmar, Marcelo Capra, Fernanda Seguro, et al.
Pageof 24